These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

159 related items for PubMed ID: 9633761

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.
    Kastrukoff LF, Morgan NG, Zecchini D, White R, Petkau AJ, Satoh J, Paty DW.
    Neurology; 1999 Jan 15; 52(2):351-9. PubMed ID: 9932956
    [Abstract] [Full Text] [Related]

  • 26. The role of interferons in the treatment of multiple sclerosis.
    Kelley CL.
    J Neurosci Nurs; 1996 Apr 15; 28(2):114-20. PubMed ID: 8718760
    [Abstract] [Full Text] [Related]

  • 27. MRI and clinical activity in MS patients after terminating treatment with interferon beta-1b.
    Richert ND, Zierak MC, Bash CN, Lewis BK, McFarland HF, Frank JA.
    Mult Scler; 2000 Apr 15; 6(2):86-90. PubMed ID: 10773853
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Enhanced spasticity in primary progressive MS patients treated with interferon beta-1b.
    Frese A, Bethke F, Lüdemann P, Stögbauer F.
    Neurology; 1999 Nov 10; 53(8):1892-3. PubMed ID: 10563657
    [No Abstract] [Full Text] [Related]

  • 30. Randomized study of interferon beta-1a, low-dose azathioprine, and low-dose corticosteroids in multiple sclerosis.
    Havrdova E, Zivadinov R, Krasensky J, Dwyer MG, Novakova I, Dolezal O, Ticha V, Dusek L, Houzvickova E, Cox JL, Bergsland N, Hussein S, Svobodnik A, Seidl Z, Vaneckova M, Horakova D.
    Mult Scler; 2009 Aug 10; 15(8):965-76. PubMed ID: 19465443
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. The clinical effect of neutralizing antibodies against interferon-beta is independent of the type of interferon-beta used for patients with relapsing-remitting multiple sclerosis.
    Koch-Henriksen N, Sorensen PS, Bendtzen K, Flachs EM.
    Mult Scler; 2009 May 10; 15(5):601-5. PubMed ID: 19299439
    [Abstract] [Full Text] [Related]

  • 34. Changes of serum sICAM-1 and MMP-9 induced by rIFNbeta-1b treatment in relapsing-remitting MS.
    Trojano M, Avolio C, Liuzzi GM, Ruggieri M, Defazio G, Liguori M, Santacroce MP, Paolicelli D, Giuliani F, Riccio P, Livrea P.
    Neurology; 1999 Oct 22; 53(7):1402-8. PubMed ID: 10534242
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. T-cell interferon gamma receptor binding in interferon beta-1b-treated patients with multiple sclerosis.
    Bongioanni P, Lombardo F, Moscato G, Mosti S, Meucci G.
    Arch Neurol; 1999 Feb 22; 56(2):217-22. PubMed ID: 10025427
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial.
    Sorensen PS, Mellgren SI, Svenningsson A, Elovaara I, Frederiksen JL, Beiske AG, Myhr KM, Søgaard LV, Olsen IC, Sandberg-Wollheim M.
    Lancet Neurol; 2009 Jun 22; 8(6):519-29. PubMed ID: 19409854
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.